Caterpillar Adds Judith Marks & James Fish, Jr. To The Board – $CAT $DIA $WM $ATOS

By John F. Heerdink, Jr.

As per reports, Caterpillar, Inc. (CAT) announced the appointment of Judith Marks, Chair, CEO and President of Otis Worldwide Corporation, and James Fish, Jr., President and CEO of Waste Management (WM), to the Caterpillar board of directors, effective March 1, 2023. Marks will serve on Caterpillar’s Audit Committee and Compensation and Human Resources Committee, while Fish will serve on Caterpillar’s Audit Committee and Sustainability & other Public Policy Committee. The company also announced that Edward Rust , 72 director since 2003 will not stand for re-election at the 2023 Annual Shareholder Meeting.

“We are pleased to welcome leaders of such high caliber to our board. With Judy’s leadership of services growth and digital transformation at Otis, and Jim’s leadership in developing sustainable solutions that support the transition to a lower-carbon economy, Caterpillar is well positioned to help our customers build a better, more sustainable world and deliver long-term profitable growth,” stated Caterpillar Chairman and CEO Jim Umpleby.

The Caterpillar board will be comprised of 11 directors, out of which 10 are independent, following the 2023 Annual Shareholder Meeting.

Dow 30 Component Caterpillar, Inc. (CAT) is the world’s chief manufacturer of diesel and natural gas engines, construction and mining equipment, industrial gas turbines, and diesel-electric locomotives. Caterpillar, Inc. also works to make sustainable progress possible and contributes to driving positive change on every continent. To learn more about Caterpillar, Inc. (CAT) and to continue to track its progress please visit the Vista Partners Caterpillar, Inc. Coverage Page.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

DID YOU KNOW?….

Approximately 1 in 8 women and one in 1,000 men will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. The American Cancer Society (ACS) estimates that approximately 270,000 women will be diagnosed with breast cancer in the United States this year. It is the second leading cause of cancer death in American women. Atossa Therapeutics, Inc. (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. Atossa is developing a drug “(Z)-endoxifen” to reduce mammographic breast density and, for patients who have recently been diagnosed with the most common type of breast cancer, to reduce tumor activity prior to surgery.

On Wednesday Jan., 25, Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced the issuance of the following Letter to Shareholders from Steven C. Quay, M.D., Ph.D., the Company’s CEO and Chairman:

Steven C. Quay, M.D., Ph.D, CEO of Atossa Therapeutics, Inc. (Nasdaq: ATOS)

TO OUR VALUED STOCKHOLDERS:

2022 was a year of significant progress for Atossa. We focused our development efforts on advancing our breast cancer program with our patented (Z)-endoxifen, the highest potency Selective Estrogen Receptor Modifier (SERM). We currently have Phase 2 studies ongoing in the prevention and treatment settings, both focused on areas of unmet medical need. Our goal is to both help reduce the incidence of breast cancer and change the treatment paradigm for patients who are not benefiting from currently approved drugs.

In October 2022, the U.S. Food and Drug Administration (FDA) authorized the initiation of our EVANGELINE study, a Phase 2 trial of (Z)-endoxifen and Exemestane + Goserelin as neoadjuvant treatment in premenopausal women with ER+/HER2- breast cancer. While there are several FDA-approved neoadjuvant therapies for ER- breast cancers, few exist for the ER+ patients, which account for approximately 78% of breast cancers. We expect to enroll approximately 175 patients at up to 25 sites across the United States.

READ THE REST OF THE PROGRESS REPORT BY CLICKING HERE.

(Read Original Story: Caterpillar Announces Appointment of Two New Independent Directors in PR Newswire)